Based on our discovery of a dominant underlying mechanism of OT resistance in our xenograft RMS models, we also credentialled PIK3CA/AKT pathway inhibition as a preclinical therapy that re-sensitizes RMS to chemotherapy-induced tumor cell killing by co-treating them with alpelisib PIK3CA inhibitor. The gene discussed is PIK3CA; the disease is neoplasm.